• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Jaguar Health, Inc. - Common Stock (NQ:JAGX)

    0.9975 +0.0663 (+7.12%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 232,578
    Open 0.9493
    Bid (Size) 0.9800 (300)
    Ask (Size) 0.9899 (200)
    Prev. Close 0.9312
    Today's Range 0.9239 - 1.020
    52wk Range 0.9174 - 33.25
    Shares Outstanding 171,350,166
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
    Via ACCESS Newswire
    News headline image
    Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
    Via ACCESS Newswire

    Performance

    YTD
    N/A
    N/A
    1 Month
    -2.2%
    -2.2%
    3 Month
    -54.5%
    -54.5%
    6 Month
    -60.7%
    -60.7%
    1 Year
    -96.3%
    -96.3%

    More News

    Read More
    News headline image
    FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
    Via ACCESS Newswire
    News headline image
    Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
    Via ACCESS Newswire
    News headline image
    Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
    Via ACCESS Newswire
    News headline image
    Get insights into the top gainers and losers of Monday's after-hours session. ↗
    Via Chartmill
    News headline image
    Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
    Via ACCESS Newswire
    News headline image
    In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial
    Via ACCESS Newswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Tuesday's after hours session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
    Via ACCESS Newswire
    News headline image
    Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates
    Via ACCESS Newswire
    News headline image
    Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting
    Via ACCESS Newswire
    News headline image
    REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and
    Via ACCESS Newswire
    News headline image
    Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Via ACCESS Newswire
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
    Via Benzinga
    News headline image
    Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)
    Via ACCESS Newswire
    News headline image
    FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease
    Via ACCESS Newswire
    News headline image
    Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
    Via ACCESS Newswire
    News headline image
    Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition
    Via ACCESS Newswire
    News headline image
    Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts
    Via ACCESS Newswire
    News headline image
    Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts
    Via ACCESS Newswire
    News headline image
    Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
    Via ACCESS Newswire
    News headline image
    Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders
    Via ACCESS Newswire
    News headline image
    Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)
    Via ACCESS Newswire

    Frequently Asked Questions

    Is Jaguar Health, Inc. - Common Stock publicly traded?
    Yes, Jaguar Health, Inc. - Common Stock is publicly traded.
    What exchange does Jaguar Health, Inc. - Common Stock trade on?
    Jaguar Health, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Jaguar Health, Inc. - Common Stock?
    The ticker symbol for Jaguar Health, Inc. - Common Stock is JAGX on the Nasdaq Stock Market
    What is the current price of Jaguar Health, Inc. - Common Stock?
    The current price of Jaguar Health, Inc. - Common Stock is 0.9975
    When was Jaguar Health, Inc. - Common Stock last traded?
    The last trade of Jaguar Health, Inc. - Common Stock was at 01/02/26 04:00 PM ET
    What is the market capitalization of Jaguar Health, Inc. - Common Stock?
    The market capitalization of Jaguar Health, Inc. - Common Stock is 170.92M
    How many shares of Jaguar Health, Inc. - Common Stock are outstanding?
    Jaguar Health, Inc. - Common Stock has 171M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.